With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.66127-01-3,3-Bromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.
66127-01-3, Synthesis of 3-(2-ferrocenylethynyl)-1,10-phenanthroline (L2): A mixture of 3-bromo-1,10-phenanthroline (120 mg, 0.46 mmol), ethynylferrocene (80 mg, 0.38 mmol), (PPh3)2PdCl2 (10 mg), CuI (8 mg) and Et3N (1 mL) in benzene (30 mL) and methanol (5 mL) was heated to reflux for 12 h under nitrogen atmosphere. Then the solvent was evaporated under reduced pressure, the residue was purified by column chromatography on silica, being eluted with CHCl3 to afford the desired product as an orange solid. Yield: 98 mg (66 %). 1H NMR (400 MHz, CDCl3): delta = 4.31 (s, 5H), 4.33 (s, 2H), 4.60 (s, 2H), 7.67 (t, J = 11.4 Hz, 1H), 7.69-7.86 (m, 2H), 8.26 (d, J = 6.8 Hz, 1H), 8.34 (s, 1H), 9.22 (d, J = 11.2 Hz,2H). ESI-HRMS: m/z 388.0657 (M+).
The synthetic route of 66127-01-3 has been constantly updated, and we look forward to future research findings.
Reference£º
Article; Ren, Mingli; Cheng, Feixiang; Asian Journal of Chemistry; vol. 27; 7; (2015); p. 2555 – 2558;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI